Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Clinical Features and Pharmacological Treatment of Dementia with Lewy Bodies

루이소체 치매의 증상과 치료

  • Kim, Tae Hui (Department of Psychiatry, Yonsei University Wonju Severance Christian Hospital)
  • 김태희 (원주세브란스기독병원 정신건강의학과)
  • Received : 2016.04.15
  • Accepted : 2016.05.16
  • Published : 2016.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Dementia with Lewy bodies (DLB) is the second most common causes of dementia. It can exhibit a variety of clinical symptoms including cognitive decline, cognitive fluctuation, visual hallucinations, parkinsonism, REM sleep behavior disorder, hypersensitivity to neuroleptics and autonomic dysfunctions. Despite more well-known criteria for DLB, there are often misdiagnosis and inappropriate treatment. It gives a lot of clinical burden to the clinician as well as to patients and families. When reducing the misdiagnosis, the burden of all will be reduced. The special concern and solicitation are needed in order not to miss the diagnosis when the cardinal features of DLB may not be volunteered by patients and the caregivers. To control the symptoms, clinicians must find and reduce drugs that can have the negative effects on DLB symptoms. There is limited evidence about specific interventions but available data suggest cholinesterase inhibitors improve the cognitive and behavioral symptoms and menmantine slightly improves the global impression.

Keywords

References

  1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124. https://doi.org/10.1212/WNL.47.5.1113
  2. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28. https://doi.org/10.1016/S1474-4422(03)00619-7
  3. Kim TH. Diagnosis and Management of Dementia with Lewy Bodies. J Korean Geriatr Psychiatry 2012;16:75-81.
  4. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34:561-566. https://doi.org/10.1093/ageing/afi190
  5. Jhoo JH, Kim KW, Huh Y, Lee SB, Park JH, Lee JJ, et al. Prevalence of dementia and its subtypes in an elderly urban korean population: results from the Korean Longitudinal Study on Health And Aging (KLoSHA). Dement Geriatr Cogn Disord 2008;26:270-276. https://doi.org/10.1159/000160960
  6. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014;44:673-683. https://doi.org/10.1017/S0033291713000494
  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013. p.618-621.
  8. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord 2010;24:177-181. https://doi.org/10.1097/WAD.0b013e3181c72b5d
  9. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord 2010;16:388-392. https://doi.org/10.1016/j.parkreldis.2010.03.007
  10. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872. https://doi.org/10.1212/01.wnl.0000187889.17253.b1
  11. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 Suppl):417-423. https://doi.org/10.3233/JAD-2006-9S347
  12. Oda H, Yamamoto Y, Maeda K. Neuropsychological profile of dementia with Lewy bodies. Psychogeriatrics 2009;9:85-90. https://doi.org/10.1111/j.1479-8301.2009.00283.x
  13. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006;129(Pt 3):729-735. https://doi.org/10.1093/brain/awh725
  14. Gnanalingham KK, Byrne EJ, Thornton A. Clock-face drawing to differentiate Lewy body and Alzheimer type dementia syndromes. Lancet 1996;347:696-697.
  15. Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:483-488. https://doi.org/10.1136/jnnp.70.4.483
  16. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-187. https://doi.org/10.1212/WNL.62.2.181
  17. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256. https://doi.org/10.1192/bjp.177.3.252
  18. Karantzoulis S, Galvin JE. Update on dementia with lewy bodies. Curr Transl Geriatr Exp Gerontol Rep 2013;2:196-204. https://doi.org/10.1007/s13670-013-0053-6
  19. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006;67:1605-1611. https://doi.org/10.1212/01.wnl.0000242630.52203.8f
  20. Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst) 2015;1:316-324.
  21. Han S, Ryu HJ, Moon TS, Kim MY, Chung IE, Han JY, et al. Validation of the Korean Lewy body composite risk score for discrimination of dementia with Lewy bodies in the Korean elderly. Neurdegener Dis 2015;15:1-1969.
  22. Cagnin A, Gnoato F, Jelcic N, Favaretto S, Zarantonello G, Ermani M, et al. Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2013;84:505-510. https://doi.org/10.1136/jnnp-2012-304095
  23. Ricci M, Guidoni SV, Sepe-Monti M, Bomboi G, Antonini G, Blundo C, et al. Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Arch Gerontol Geriatr 2009;49:e101-e104. https://doi.org/10.1016/j.archger.2008.10.001
  24. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 2008;46:101-106. https://doi.org/10.1016/j.archger.2007.03.003
  25. Galasko DR. Dementia with Lewy bodies. Continnum Lifelong Learning Neurol Clin 2007;13:69-86. https://doi.org/10.1212/01.CON.0000267236.07498.38
  26. Fahn S, Elton R. Members of the updrs Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Health Care Information;1987. p.153-163, 293-304.
  27. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997;96:366-371.
  28. Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazui H, et al. Occipital glucose metabolism in dementia with lewy bodies with and without Parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord 2001;12:194-197. https://doi.org/10.1159/000051257
  29. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 2008;23 Suppl 3:S521-S533. https://doi.org/10.1002/mds.22049
  30. Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. Eur J Neurol 2009;16:212-217. https://doi.org/10.1111/j.1468-1331.2008.02388.x
  31. Whitworth HB. A Caregiver's Guide to Lewy Body Dementia. New York: Demos Health;2011. p.37-40.
  32. Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16 Suppl 1:S12-S18. https://doi.org/10.1002/1099-1166(200112)16:1+<::AID-GPS562>3.0.CO;2-3
  33. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry 2004;65 Suppl 11:16-22.
  34. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-1300. https://doi.org/10.1212/01.wnl.0000340980.19702.6e
  35. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-577. https://doi.org/10.1016/S1474-4422(06)70476-8
  36. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011;77:875-882. https://doi.org/10.1212/WNL.0b013e31822c9148
  37. Fernandez-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep 2016;39:121-132. https://doi.org/10.5665/sleep.5332
  38. Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin SC, Bieniek K, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445-453. https://doi.org/10.1016/j.sleep.2010.12.009
  39. Boeve BF, Molano JR, Ferman TJ, Lin SC, Bieniek K, Tippmann-Peikert M, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med 2013;9:475-480.
  40. Neikrug AB, Ancoli-Israel S. Diagnostic tools for REM sleep behavior disorder. Sleep Med Rev 2012;16:415-429. https://doi.org/10.1016/j.smrv.2011.08.004
  41. Boeve BF, Silber MH, Ferman TJ. Current management of sleep disturbances in dementia. Curr Neurol Neurosci Rep 2002;2:169-177. https://doi.org/10.1007/s11910-002-0027-0
  42. Ferman TJ, Smith GE, Dickson DW, Graff-Radford NR, Lin SC, Wszolek Z, et al. Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. Alzheimers Res Ther 2014;6:76. https://doi.org/10.1186/s13195-014-0076-z
  43. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006;77:468-473. https://doi.org/10.1136/jnnp.2005.074070
  44. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004;63:1093-1095. https://doi.org/10.1212/01.WNL.0000138500.73671.DC
  45. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013;28:597-604. https://doi.org/10.1002/mds.25445
  46. Chiba Y, Fujishiro H, Iseki E, Ota K, Kasanuki K, Hirayasu Y, et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:273-281. https://doi.org/10.1159/000339363
  47. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 2015;172:731-742. https://doi.org/10.1176/appi.ajp.2015.14121582
  48. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504.
  49. Ballard CG, Chalmers KA, Todd C, McKeith IG, O'Brien JT, Wilcock G, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68:1726-1729. https://doi.org/10.1212/01.wnl.0000261920.03297.64
  50. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125(Pt 2):391-403. https://doi.org/10.1093/brain/awf033
  51. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52. https://doi.org/10.1002/ana.23557
  52. Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015;7:4. https://doi.org/10.1186/s13195-014-0083-0
  53. Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimers Res Ther 2015;7:5. https://doi.org/10.1186/s13195-014-0081-2
  54. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036. https://doi.org/10.1016/S0140-6736(00)03399-7
  55. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007;23:401-405. https://doi.org/10.1159/000101512
  56. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618. https://doi.org/10.1016/S1474-4422(09)70146-2
  57. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-977. https://doi.org/10.1016/S1474-4422(10)70194-0
  58. Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2011;32:227-234. https://doi.org/10.1159/000334523
  59. Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015;30:46-54. https://doi.org/10.1002/gps.4109
  60. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002;13:67-73. https://doi.org/10.1159/000048636
  61. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999;14:459-466. https://doi.org/10.1002/(SICI)1099-1166(199906)14:6<459::AID-GPS957>3.0.CO;2-R
  62. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:549-553. https://doi.org/10.1016/S0278-5846(03)00040-X
  63. Kurlan R, Cummings J, Raman R, Thal L; Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-1363. https://doi.org/10.1212/01.wnl.0000260060.60870.89
  64. Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord 2010;24:360-364. https://doi.org/10.1097/WAD.0b013e3181e6a4d7
  65. Varanese S, Perfetti B, Gilbert-Wolf R, Thomas A, Onofrj M, Di Rocco A. Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. Int J Geriatr Psychiatry 2013;28:1095-1097. https://doi.org/10.1002/gps.3952
  66. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23:2248-2250. https://doi.org/10.1002/mds.22322